1. Home
  2. BPMC vs BIO Comparison

BPMC vs BIO Comparison

Compare BPMC & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BPMC
  • BIO
  • Stock Information
  • Founded
  • BPMC 2008
  • BIO 1952
  • Country
  • BPMC United States
  • BIO United States
  • Employees
  • BPMC N/A
  • BIO N/A
  • Industry
  • BPMC Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • BPMC Health Care
  • BIO Industrials
  • Exchange
  • BPMC Nasdaq
  • BIO Nasdaq
  • Market Cap
  • BPMC 8.3B
  • BIO 6.0B
  • IPO Year
  • BPMC 2015
  • BIO N/A
  • Fundamental
  • Price
  • BPMC $129.36
  • BIO $252.04
  • Analyst Decision
  • BPMC Buy
  • BIO Strong Buy
  • Analyst Count
  • BPMC 20
  • BIO 4
  • Target Price
  • BPMC $127.82
  • BIO $324.25
  • AVG Volume (30 Days)
  • BPMC 3.4M
  • BIO 369.5K
  • Earning Date
  • BPMC 07-31-2025
  • BIO 07-31-2025
  • Dividend Yield
  • BPMC N/A
  • BIO N/A
  • EPS Growth
  • BPMC N/A
  • BIO N/A
  • EPS
  • BPMC N/A
  • BIO N/A
  • Revenue
  • BPMC $562,121,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • BPMC $44.46
  • BIO N/A
  • Revenue Next Year
  • BPMC $32.78
  • BIO $3.42
  • P/E Ratio
  • BPMC N/A
  • BIO N/A
  • Revenue Growth
  • BPMC 99.19
  • BIO N/A
  • 52 Week Low
  • BPMC $73.04
  • BIO $211.43
  • 52 Week High
  • BPMC $129.49
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • BPMC 76.87
  • BIO 60.17
  • Support Level
  • BPMC $129.00
  • BIO $245.87
  • Resistance Level
  • BPMC $129.49
  • BIO $264.68
  • Average True Range (ATR)
  • BPMC 0.25
  • BIO 6.93
  • MACD
  • BPMC -0.92
  • BIO 1.36
  • Stochastic Oscillator
  • BPMC 90.91
  • BIO 60.80

About BPMC Blueprint Medicines Corporation

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: